Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.37 |
| ▸ | FDPS | P14324 | 9/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22414336 | 1.00 | TSHR (0.40) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL5198960 | 0.85 | TSHR (0.40) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL22448942 | 0.85 | TSHR (0.40) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL20643823 | 0.83 | EPHX1 (0.44) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL19352948 | 0.83 | EPHX1 (0.39) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL24045162 | 0.83 | EPHX1 (0.39) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL18525926 | 0.83 | EPHX1 (0.39) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL24927622 | 0.82 | EPHX1 (0.50) | TSHRTHRBEPHX1GGPS1FDPS | |
| SCHEMBL23220284 | 0.81 | FDPS (0.38) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL21790405 | 0.81 | EPHX1 (0.42) | TSHRTHRBEPHX1GGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688481-B2 | Ruthenium complexes useful for catalyzing metathesis reactions | XIMO AG (DE) | 2020-06-23 | — | — | US | disclosed |
| US-20190210012-A1 | RUTHENIUM COMPLEXES USEFUL FOR CATALYZING METATHESIS REACTIONS | VERBIO SE (DE) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688481-B2 | Ruthenium complexes useful for catalyzing metathesis reactions | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, RFC1 | TSHR 1450/4885THRB 2541/4885EPHX1 4126/4885 |
| US-20190210012-A1 | RUTHENIUM COMPLEXES USEFUL FOR CATALYZING METATHESIS REACTIONS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, RFC1 | TSHR 1450/4885THRB 2541/4885EPHX1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.